Oncorus Announces Four Presentations at AACR Annual Meeting 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Oncorus, Inc., an oncolytic virus therapeutics company focused on driving innovation to transform outcomes for cancer patients, announced today that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29 through April 3, 2019 at the Georgia World Congress Center in Atlanta, GA.

Oncorus will give an oral presentation highlighting preclinical data supporting the advancement of its lead pipeline candidate, ONCR-177, a locally administered oncolytic virus therapy armed with five immunomodulatory payloads for the treatment of multiple solid tumor indications. ONCR-177 is built on Oncorus’ proprietary, next-generation oncolytic herpes simplex virus (oHSV) platform. The company’s three poster presentations will detail proprietary innovations in potency and safety engineered by Oncorus into both its oHSV platform as well as its novel synthetic oncolytic virus platform that enable best-in-class potential for the company’s portfolio programs and the opportunity to pursue multiple tumor indications

“Our research team under the leadership of our CSO, Dr. Christophe Quéva, continues to make rapid progress advancing both our oncolytic herpes simplex virus and synthetic oncolytic virus platforms to enable intratumoral and intravenous administration of oncolytic virus therapies, respectively, that have the potential to address a spectrum of critical, unmet cancer treatment needs,” said Ted Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. “We look forward to sharing our proprietary innovations on both platforms at this year’s AACR Annual Meeting, in particular preclinical data supporting the clinical advancement of our lead candidate ONCR-177.”

The schedule and details for Oncorus’ oral and poster presentations are as follows:

Oral Presentation

Abstract #: 940
Title: Development of ONCR-177, a miR-attenuated oncolytic HSV-1 designed to potently activate systemic antitumor immunity
Session: MS.IM02.03 - Cancer Vaccines and Intratumoral Immunomodulation
Date and Time: Sunday, March 31, 2019 / 3:05 – 3:20 pm EDT
Location: Georgia Ballroom 3 – Building C
Abstract Link: https://www.abstractsonline.com/pp8/#!/6812/presentation/2236

Poster Presentations

Abstract #: 1455
Title: Design of ONCR-177 base vector, a next generation oncolytic herpes simplex virus type-1, optimized for robust oncolysis, transgene expression and tumor-selective replication
Session: PO.IM02.08 -- Cancer Vaccines and Intratumoral Immunomodulation
Date and Time: Monday, April 1, 2019 / 8:00 am – 12:00 pm EDT
Location: Poster Section 22
Abstract Link: https://www.abstractsonline.com/pp8/#!/6812/presentation/2749

Abstract #: 1452
Title: Development of ONCR-148, a miR-attenuated oncolytic HSV-1 designed to potently activate antitumor T cell response
Session: PO.IM02.08 -- Cancer Vaccines and Intratumoral Immunomodulation
Date and Time: Monday, April 1, 2019 / 8:00 am – 12:00 pm EDT
Location: Poster Section 22
Abstract Link: https://www.abstractsonline.com/pp8/#!/6812/presentation/2746

Abstract #: 4773
Title: Development of ONCR-NEP, a lipid nanoparticle delivered oncolytic virus capable of robust in situ amplification resulting in tumor lysis and regression
Session: PO.ET08.01 -- Gene- and Vector-based Therapy
Date and Time: Wednesday, April 3, 2019 / 8:00 am – 12:00 pm EDT
Location: Poster Section 12
Abstract Link: https://www.abstractsonline.com/pp8/#!/6812/presentation/1354

About Oncorus

At Oncorus, we are driving innovation to deliver next-generation, best-in-class oncolytic virus therapies to transform outcomes for cancer patients. We are advancing a portfolio of locally and systemically administered oncolytic virus therapies for a broad spectrum of indications with significant unmet needs based on our oncolytic herpes simplex virus (oHSV) and synthetic oncolytic virus platforms. Our team has engineered proprietary, multidimensional innovations into both platforms to enable us to deliver on the full potential of oncolytic virus therapies to dramatically improve outcomes for cancer patients. Please visit www.oncorus.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005225/en/